Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.45 |
| ▸ | TFPI2 | P48307 | 4/20 | 0.42 |
| ▸ | PPP5C | P53041 | 2/20 | 0.42 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PPM1B | O75688 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9880146 | 0.83 | TFPI2 (0.60) | TFPI2PPP5CPPP2CANPY4RKMT2A | |
| SCHEMBL9880152 | 0.80 | ALDH1A1 (0.54) | KMT2ACYP2C19KDM4E | |
| SCHEMBL9880141 | 0.80 | TFPI2 (0.56) | HSD11B1TFPI2PPP5CPPP2CANPY4R | |
| SCHEMBL14135612 | 0.78 | TFPI2 (0.46) | TFPI2PPP5CPPP2CANPY4RKMT2A | |
| SCHEMBL16451149 | 0.78 | PPM1B (0.45) | TFPI2PPP5CPPP2CANPY4RKMT2A | |
| SCHEMBL16731305 | 0.78 | TFPI2 (0.70) | HSD11B1TFPI2PPP5CPPP2CANPY4R | |
| SCHEMBL9880154 | 0.78 | TFPI2 (0.70) | HSD11B1TFPI2PPP5CPPP2CANPY4R | |
| SCHEMBL21360341 | 0.77 | TFPI2 (0.45) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL9880144 | 0.77 | TFPI2 (0.45) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL9880149 | 0.76 | RECQL (0.46) | TFPI2PPP5CPPP2CANPY4RKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3258930-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS | LIXTE BIOTECHNOLOGY INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-10668062-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes | LIXTE BIOTECHNOLOGY, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10413541-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| WO-2019113155-A1 | OXABICYCLOHEPTANES FOR TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIA | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190167671-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | LIXTE BIOTECHNOLOGY, INC. | 2019-06-06 | — | — | US | disclosed |
| EP-2870161-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF REPERFUSION INJURY | LIXTE BIOTECHNOLOGY INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-2714924-B1 | HDAC Inhibitors for use in the treatment of Gaucher's disease, von Hippel-Lindau disease, phaeochromocytoma and paragangliomas. | LIXTE BIOTECHNOLOGY INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20120270736-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120135522-A1 | METHODS OF MODULATING CELL REGULATION BY INHIBITING P53 | LIXTE BIOTECHNOLOGY, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20110287537-A1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY, INC. | 2011-11-24 | — | — | US | disclosed |
| US-8058268-B2 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| WO-2008097561-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHOLOGY HOLDINGS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | SNCA, NLN, HTT | HSD11B1 3299/4885TFPI2 4324/4885PPP5C 2709/4885 |
| US-20120270736-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | HSD11B1 56/4885TFPI2 4858/4885PPP5C 3037/4885 |
| US-10413541-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | HSD17B11, HSD17B1, CRH | HSD11B1 6/4885TFPI2 4289/4885PPP5C 2219/4885 |
| US-20190167671-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | PPP2CA, PPP3CA, PPP6C | HSD11B1 298/4885TFPI2 3732/4885PPP5C 12/4885 |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | HCCS, VHL, OXA1L | HSD11B1 79/4885TFPI2 4843/4885PPP5C 2860/4885 |
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | HSD11B1 56/4885TFPI2 4858/4885PPP5C 3037/4885 |
| US-10668062-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes | PPP2CA, PPP3CA, PPP6C | HSD11B1 298/4885TFPI2 3732/4885PPP5C 12/4885 |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | HSD11B1 56/4885TFPI2 4858/4885PPP5C 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.